Patient Stories for Anxiety

by | Jun 14, 2010

TRANQUIL CLARITY ™
Stress Relief Formula

BENEFITS
– Calms the Nervous System
– Increases Mental Acuity
– Enhances Physical Stamina
– Reduces Physical and Mental Fatigue

PATIENT STORIES

Sarah, Scottsdale, Arizona

A few years ago I was so stressed that I could no longer effectively function. As a mother with a small child and working waiting tables at a very busy restaurant, I felt overwhelmed by stress. The mental fatigue and raw nerves were more than I could stand. I felt jittery inside all of the time and I could never get a calm night’s sleep. Dr. Hansen’s Stress Relief formula Tranquil Clarity changed all of that. Within a very short time I felt a serenity and calm come over me that I had not known existed. I was sleeping better, I had more energy and I was a cheerful wife and Mom again.


Christi, Phoenix, Arizona

As a graduate student I learned what stress was all about. I was always anxious, hurried and pressured. Dr. Hansen’ Stress Relief formula Tranquil Clarity helps me to stay calm and clear while I am taking tests! I still need to study, but Tranquil Clarity keeps me calm and focused.


Craig, Dallas, Texas

I have always been a quick thinking and acting, self-motivated active person. I own two companies, am a father of four daughters, very active in church service in my community and just on the go all the time. By age 42, my rushed pace and overwhelming schedule of deadlines, commitments, presentations, executive negotiations had nearly burned out my nervous system. I felt stressed all of the time. There seemed to be a continuous jittery nervousness in my stomach and muscles all of the time. Then I discovered Dr. Hansen’s Stress Relief formula Tranquil Clarity. The stress, deadlines, commitments and rushed pace are still there, but now I feel a calm inner strength that allows me to handle it. And when I feel the pressure building up and the anxiousness returning, I just take more Tranquil Clarity. It works quickly without any side-effects and even seems to improve my focus, mental clarity, memory and negotiation skills. It’s truly phenomenal.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

7 + 4 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });